![Amgen](https://trials-media.s3.amazonaws.com/orgs/amgen.jpeg)
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic...
MelanomaThe purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma.
![Obsidian Therapeutics, Inc.](https://trials-media.s3.amazonaws.com/orgs/obsidian-therapeutics-inc.jpeg)
Safety and Efficacy of OBX-115 in Advanced/Metastatic Melanoma Resistant to Immune Checkpoint Inhibitors...
Tumor SkinMetastatic Melanoma1 moreThis is a study to investigate the safety and efficacy of an investigational regimen, OBX-115, in adult participants with advanced/metastatic melanoma.
![University of Zurich](https://trials-media.s3.amazonaws.com/orgs/university-of-zurich.jpeg)
Intrathecal Double Checkpoint Inhibition
Leptomeningeal MetastasisNon-small Cell Lung Cancer Stage IV1 moreThe objective of the present study is to determine the feasibility and to explore anti-tumor activity of intrathecal double immune checkpoint inhibition for patients with newly diagnosed leptomeningeal metastases from non-small cell lung cancer without driver mutation or melanoma.
![C4 Therapeutics, Inc.](https://trials-media.s3.amazonaws.com/orgs/c4-therapeutics-inc.jpeg)
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy...
Solid TumorsMelanoma3 moreThe purpose of this study is to evaluate the safety and tolerability of CFT1946 as well as to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CFT1946 as monotherapy (Arm A) and in combination with trametinib (CFT1946 + trametinib; Arm B).
![Peking University Cancer Hospital & Institute](https://trials-media.s3.amazonaws.com/orgs/peking-university-cancer-hospital-and-institute.jpeg)
Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma
MelanomaThe study was a single-arm study designed to evaluate the efficacy and safety of Chidamide combined with Toripalimab.
![Turnstone Biologics, Corp.](https://trials-media.s3.amazonaws.com/orgs/turnstone-biologics-corp.jpeg)
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
Breast CancerColorectal Cancer4 moreA multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.
![Lyell Immunopharma, Inc.](https://trials-media.s3.amazonaws.com/orgs/lyell-immunopharma-inc.jpeg)
A Study to Investigate LYL845 in Adults With Solid Tumors
MelanomaNon-small Cell Lung Cancer1 moreThis is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).
![Amgen](https://trials-media.s3.amazonaws.com/orgs/amgen.jpeg)
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected...
MelanomaThe purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma.
![IDEAYA Biosciences](https://trials-media.s3.amazonaws.com/orgs/ideaya-biosciences.jpeg)
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Uveal MelanomaNeoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
![Hoffmann-La Roche](https://trials-media.s3.amazonaws.com/orgs/hoffmann-la-roche.jpeg)
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or...
MelanomaThe purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics of two dose levels of RO7247669 in participants with unresectable or metastatic melanoma to select the recommended dose for further development.